|Day Low/High||0.03 / 0.04|
|52 Wk Low/High||0.02 / 0.30|
VANCOUVER, British Columbia, Dec. 18, 2018 /PRNewswire/ -- Abattis Bioceuticals Corp (the " Company" or " Abattis") (CSE:ATT) (OTC:ATTBF) is pleased to announce its first proprietary product, Comfort, which has been produced through wholly owned...
VANCOUVER, British Columbia, November 27, 2018 /PRNewswire/ -- Abattis Bioceuticals Corp (the " Company" or " Abattis") (CSE: ATT) (OTC: ATTBF) is pleased to announce that the Company has signed a Distribution Agreement (the " Distribution Agreement")...
Northern Vine Laboratories Selected to Provide Hemp Extract, and Research & Development and Analytical Testing Services to Develop CBD Beer
Abattis looks to become a leader in extraction with proprietary extraction technology
Emerald and Abattis positioned to grow analytical testing and import opportunities facilitated by Northern Vines' recently renewed Licensed Dealer Laboratory
GW Pharmaceuticals saw its stock price surge amid news of a successful Epidiolex clinical trial. But that high also generated buzz across pot stocks at large.
Companies in the cannabis business have an appetite for capital to fuel what has emerged as one of the largest growth sectors, and more investors are taking the risk.
Abattis Bioceuticals Signs $25 Million Deal With Dutchess Fund
The Toronto-based wealth management and securities company helped aspiring pot grower Enertopia raise over a million dollars but, upon being informed by TheStreet that it had been credited in a regulatory filing, Canaccord wasn't feeling the vibes.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.